Finalized CMS Rule Supports Medicare Coverage for Gene Therapy
- CMS finalized a decision to provide Medicare coverage for chimeric antigen receptor (CAR) T-cell therapy, which is an FDA-approved gene therapy used to treat non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia. “Today’s coverage decision provides consistent and predictable patient access nationwide,” said CMS...
